curriculum vitae - pathology · curriculum vitae name: gregor krings, md, phd position: assistant...

Prepared: February 11, 2019

1 of 27

University of California, San Francisco

CURRICULUM VITAE

Name: Gregor Krings, MD, PhD

Position: Assistant Professor of Clinical Pathology, Step 4

Pathology

School of Medicine

Address: UCSF Department of Pathology

1825 4th Street

Box 4066, Room M2355

San Francisco, CA 94143-4066

Email: [email protected]

EDUCATION

1993 - 1994 Virginia State and

Polytechnic Institute,

Blacksburg, Virginia

1994 - 1997 University of

Georgia, Athens,

Georgia

B.A. Anthropology

1999 - 2008 Medical University of

South Carolina,

Charleston, South

Carolina

M.D. Medicine (Medical

Scientist Training

Program)

1999 - 2008 Medical University of

South Carolina,

Charleston, South

Carolina

Ph.D. Molecular and Cellular

Biology

Advisor: Deepak

Bastia

2008 - 2010 Massachusetts

General Hospital,

Boston,

Massachusetts

Resident

physician

Pathology


California (UCSF),

San Francisco,

California

Resident

physician

Pathology


California (UCSF),

San Francisco,

California

Clinical

fellow

Surgical and

Gastrointestinal/Liver

Pathology


2 of 27


California (UCSF),

San Francisco,

California

Clinical

research

fellow

Pathology Laboratory of

Barbara Panning

(Biochemistry &

Biophysics)

LICENSES, CERTIFICATION

2010 Medical licensure, California

2012 Board Certification in Anatomic Pathology, American Board of Pathology

PRINCIPAL POSITIONS HELD

1998 - 1999 Medical University of South Carolina,

Charleston, South Carolina

Post-graduate

researcher

Medicine,

Microbiology

2013 - 2014 University of California (UCSF), San

Francisco, California

Health Sciences

Clinical Instructor,

Breast Pathology

Pathology

2014 - present University of California (UCSF), San


Assistant

Professor of

Clinical Pathology

Pathology

OTHER POSITIONS HELD CONCURRENTLY

2008 - 2010 Harvard Medical School, Boston,

Massachusetts

Clinical Fellow Pathology

2011 - 2013 University of California (UCSF), San


Health Sciences

Clinical Instructor

Pathology

2013 - 2013 Beth Israel Deaconess Medical Center,

Harvard Medical School, Boston,

Massachusetts

Observer Breast

Pathology

(under Dr.

Stuart Schnitt)

HONORS AND AWARDS

2000 Summer Health Professionals

Research Fellowship Award

Medical University of South Carolina

2000 Medical Scientist Training Program

(National Institutes of Health) Training

Grant


2001 Thomas W. Holbrook Award in

Pathology and Microbiology


2003 2nd place prize (poster division,

Ph.D.), Student Research Day


2004 1st place prize (oral division, Ph.D.),

Student Research Day



3 of 27

2005 2nd place prize (oral division, Ph.D.),

Student Research Day


2006 Program for Excellence in Science American Association for the

Advancement of Science (AAAS)

2006 Provost Scholarship Medical University of South Carolina

2006 Alpha Omega Alpha medical honor

society

2007 Arnold P. Gold Humanism Honor

Society

2008 Distinguished Graduate Student Award Medical University of South Carolina

KEYWORDS/AREAS OF INTEREST Breast cancer, cancer genomics; neoplastic precursor lesions of the breast; fibroepithelial lesions; molecular diagnostics; molecular pathology.

CLINICAL ACTIVITIES

CLINICAL ACTIVITIES SUMMARY As a surgical pathologist with expertise in breast pathology, my clinical mission is to provide dedicated pathology services to UCSF patients with subspecialty focus on breast pathology. In this capacity, my practice primarily includes patients at the UCSF Carol Franc Buck Breast Care Center, and I attend on the Breast Pathology service at the Mission Bay campus. Given that UCSF is a tertiary care center with an internationally recognized clinical breast care service, these cases are often highly complex and require specialized expertise. In this role, I also provide diagnostic confirmation services for breast specimens obtained at other facilities from patients seeking to further their care at UCSF. I also provide diagnostic consultation services for second opinion of diagnostically challenging breast pathology cases sent by pathologists at other institutions. I attend and present at weekly multidisciplinary tumor board meetings for the clinical breast service at the Breast Care Center. I am a member of the UCSF Clinical Cancer Genomics Laboratory (CCGL). I provide diagnostic genetic molecular pathology services for tumors profiled with a targeted next generation DNA sequencing panel of cancer genes (UCSF500 cancer gene panel). My expertise includes the genomics of breast cancer, in addition to a wide variety of other tumor types. I also sign out ERBB2 fluorescence in situ hybridization (FISH) assays in breast and other cancers as needed. I attend and present at weekly multidisciplinary molecular tumor board meetings, at which genomics findings are discussed and integrated into a treatment plan. I attend on the Gastrointestinal/Liver Pathology service as a minor clinical focus, which primarily includes endoscopic and imaging-guided gastrointestinal biopsies, native and transplant liver biopsies. Additional surgical pathology services include rapid intraoperative frozen section coverage at Mission Bay and Mt. Zion hospitals and night call coverage at the Mission Bay campus.


4 of 27

CLINICAL SERVICES

2013 - present UCSF Pathology, Breast (cluster A) and

Gastrointestinal/Liver (cluster B) services, Attending

pathologist

~60% total effort

(~95% clinical

service effort)

2015 - present Clinical Cancer Genomics Laboratory, UCSF500 Cancer

Gene Panel signout, Attending molecular pathologist

1/2 day per week

2016 - present Clinical Cancer Genomics Laboratory, HER2 FlSH signout,

Attending molecular pathologist

As needed

2012 - 2013 UCSF Pathology, overnight and weekend call

(intraoperative frozen section, rapid evaluation of donor

biopsies for transplantation, rush cases)

~5-6 weeks per

year

PROFESSIONAL ACTIVITIES

MEMBERSHIPS

1999 - 2000 American Medical Student Association (AMSA)

2006 - 2008 American College of Physicians (ACP), student member

2006 - 2007 American Association for the Advancement of Science (AAAS)

2006 - present Alpha Omega Alpha (AOA) Medical Honor Society

2007 - present Arnold P. Gold Humanism Honor Society

2008 - present College of American Pathologists (CAP)

2008 - 2010 Association for Molecular Pathology (AMP)

2013 - 2017 Association for Molecular Pathology (AMP)

2013 - present United States and Canadian Academy of Pathology (USCAP)

SERVICE TO PROFESSIONAL ORGANIZATIONS

2015 - present NRG Oncology Pathology Committee Core member

2017 - United States and Canadian Academy of Pathology

(USCAP) 106th Annual Meeting, San Antonio, TX

Moderator (invited),

Platform

presentations,

Breast Pathology

2018 - 2020 United States and Canadian Academy of Pathology

(USCAP) Annual Meeting (2018-2020 meetings)

Abstract Review

Board (invited 3-

year term), Breast

Pathology section

2018 - United States and Canadian Academy of Pathology

(USCAP) 107th Annual Meeting, Vancouver, British

Columbia

Moderator (invited),

Platform

presentations,

Breast Pathology


5 of 27

SERVICE TO PROFESSIONAL PUBLICATIONS

2017 - Ad hoc reviewer, Human Pathology Case Reports

2017 - Ad hoc reviewer, Breast Cancer Research

INVITED PRESENTATIONS - INTERNATIONAL

2017 United States and Canadian Academy of Pathology

(USCAP), 106th Annual Meeting, San Antonio. "Genomic

Profiling of Secretory Carcinoma."

Presenter, platform


(USCAP), 107th Annual Meeting, Vancouver, British

Columbia, Canada. "Genomic Profiling of Metaplastic

Carcinoma and Associated in Situ Carcinoma of the

Breast."

Presenter, platform


(USCAP), 108th Annual Meeting, National Harbor,

Maryland. "Genetics of Flat Epithelial Atypia and Early

Neoplastic Progression in the Breast."

Presenter, platform

INVITED PRESENTATIONS - NATIONAL

2015 UCSF Postgraduate Course in Breast and Endocrine

Surgery, March 6-7th, 2015, San Francisco, CA

Presenter and

panel discussant

2015 "Fibroepithelial Lesions of the Breast", 31st Annual UCSF

Current Issues in Anatomic Pathology CME course, May

21st-23rd, 2015, San Francisco, CA

Lecturer

2016 "Solid Pattern Lesions of the Breast", 32nd Annual UCSF


26-28th, 2016, San Francisco, CA

Lecturer

2018 "Updates on Diagnosis and Management of Borderline

and High Risk Breast Lesions on Core Needle Biopsy",

34th Annual UCSF Current Issues in Anatomic Pathology

CME course, May 24th-26th, 2018, San Francisco, CA

Lecturer

2019 "Spindle Cell Lesions of the Breast", 35th Annual UCSF


23rd-25th, 2019, San Francisco, CA

Lecturer

CONTINUING EDUCATION AND PROFESSIONAL DEVELOPMENT ACTIVITIES

2010 "Gastrointestinal, Liver, and Pancreatic Pathology", Massachusetts General

Hospital, Boston, Massachusetts

2010 "Seminars in Pathology", 63rd Annual Convention of California Society of

Pathologists, San Francisco, California


6 of 27

2011 United States and Canadian Academy of Pathology 100th Annual Meeting, San

Antonio, Texas

2012 United States and Canadian Academy of Pathology 101st Annual Meeting,

Vancouver, British Columbia

2012 UCSF Current Issues in Anatomic Pathology, San Francisco, California

2013 United States and Canadian Academy of Pathology 102nd Annual Meeting,

Baltimore, Maryland

2013 66th Annual Convention of California Society of Pathologists, San Francisco,

California

2013 "Breast Pathology. Current Concepts and Controversies", Harvard Medical

School, Boston, Massachusetts

2013 San Antonio Breast Cancer Symposium, San Antonio, Texas

2014 United States and Canadian Academy of Pathology 103rd Annual Meeting, San

Diego, California

2014 San Antonio Breast Cancer Symposium, San Antonio, Texas

2015 United States and Canadian Academy of Pathology 104th Annual Meeting,

Boston, Massachusetts

2015 "Updates in the Changing World of Breast Pathology", California Tumor Tissue

Registry, San Francisco, California

2015 Current Issues in Anatomic Pathology, San Francisco, California

2016 United States and Canadian Academy of Pathology 105th Annual Meeting,

Seattle, Washington

2016 Current Issues in Anatomic Pathology, San Francisco, California

2017 United States and Canadian Academy of Pathology 106th Annual Meeting, San

Antonio, TX

2018 UCSF Current Issues in Anatomic Pathology, San Francisco, California

UNIVERSITY AND PUBLIC SERVICE

SERVICE ACTIVITIES SUMMARY I serve on the core committee tasked with organizing an annual UCSF Pathology research retreat (2017, 2018) aimed at highlighting the broad scope of basic science and clinical research in the Pathology Department. As the Mission Bay campus site director for the UCSF School of Medicine pathology rotation for medical students, my responsibilities have included designing, implementing and supervising a practical surgical pathology experience and serving as the primary point person for medical students during their rotation through the Pathology department at Mission Bay.


7 of 27

I organize and lead the monthly orientation of Anatomic Pathology residents and fellows rotating onto the Breast Pathology service at the Mission Bay hospital. In preparation for the move to the Mission Bay hospital, I served as the faculty lead for visual media for the new site, being responsible for evaluation of visual media needs (photography, streaming video) for clinical gross specimen photography. I continue to serve in this role for the Mission Bay campus as needed.

SCHOOL OF MEDICINE

2015 - 2018 UCSF School of Medicine, Pathology rotation Site director for

medical students,

Mission Bay

campus

DEPARTMENTAL SERVICE

2019 -

Breast Pathology Fellowship, UCSF Department of

Pathology

Director

2017 - UCSF Department of Pathology, Research Retreat Organizational

core committee

member

2017 - 2017 UCSF Department of Pathology, proctoring of clinical

instructor in breast pathology (Dr. Gregory Bean)

Clinical proctor

2016 - 2016 UCSF Department of Pathology/Clinical Cancer

Genomics Laboratory

Faculty search

committee

member

2016 - 2016 UCF Department of Pathology, Workflow integration of

molecular pathology reporting with surgical pathology

Co-lead

2015 - 2018 UCSF School of Medicine, Pathology rotation Site director for

medical students,

Mission Bay

campus

2014 - Project faculty lead for gross specimen photography,

Mission Bay Hospital, UCSF Department of Pathology.

Faculty Lead

2014 - Breast pathology service resident and fellow orientation,

UCSF Department of Pathology

Lead


8 of 27

2012 - Surgical Pathology Quarterly Meeting, UCSF Department

of Pathology

Participant

COMMUNITY AND PUBLIC SERVICE

2018 - East Bay German International School Volunteer, school

and community

events

TEACHING AND MENTORING

TEACHING SUMMARY Residency and fellowship teaching: My primary teaching activity is diagnostic surgical pathology with a primary breast and secondary gastrointestinal focus to junior and senior residents, surgical pathology fellows, and breast and GI/liver subspecialty fellows. I also teach breast surgery fellows and visiting scholars rotating through our department. Teaching is primarily microscope-based during daily clinical signout and also includes gross specimen evaluation and dissection. I also teach cancer clinical genomics via the UCSF500 targeted next generation sequencing assay on an ad hoc basis. I present a series of formal diagnostic breast pathology lectures to pathology residents and fellows for the Resident Teaching Conference (RTC) curriculum, a year-round lecture series that covers all major aspects of modern surgical pathology. I contribute approximately 50% of the breast pathology lectures in this series. In addition, I prepare breast pathology slide sets and practical slide teaching sessions for housestaff. Medical student teaching: I have served as a small group leader in the Mechanisms, Methods, and Malignancies (M3) section of the School of Medicine (SOM) curriculum and as laboratory instructor for the SOM GAP labs. I also assist in teaching the surgical pathology component of the Medical Student Pathology Elective for students rotating on the surgical pathology service. Continuing Medical Education (CME) teaching: I lecture to pathologists at the annual UCSF 'Current Issues in Anatomic Pathology' CME meeting on an invited basis.

FORMAL TEACHING

Academic Yr Course No. & Title Teaching

Contribution

School Class

Size

2010 - 2011 Interdepartmental

Studies (IDS) 101:

Prologue

Laboratory

instructor/facilitator:

acute and chronic

inflammation (1

session), neoplasia

(1 session)

Medicine 30-40


9 of 27


Contribution

School Class

Size


Studies (IDS) 102B:

Organ Systems:

Topics in Renal and

Pulmonary

Pathophysiology

Laboratory


glomerular diseases

(1 session)

Medicine 30-40


Studies (IDS) 103A:

Metabolism and

Nutrition

Laboratory


upper

gastrointestinal

system (1 session)

Medicine 30-40


Studies (IDS) 103A:

Metabolism and

Nutrition

Laboratory


liver (1 session),

lower gastrointestinal

system (1 session)

Medicine 30-40


Studies (IDS) 106:

Mechanisms,

Methods, and

Malignancies (M3)

Small group leader:

Classification of

Neoplasms (1

session)

Medicine 13


Studies (IDS) 102B:

Organ Systems:

Topics in Renal and

Pulmonary

Pathophysiology

Laboratory


Obstructive and

restrictive pulmonary

diseases (1 session)

Medicine 15-25


Studies (IDS) 103A:

Metabolism and

Nutrition

Laboratory


liver (1 session),

lower gastrointestinal

system (1 session),

upper

gastrointestinal

system (1 session),

pancreas (1 session)

Medicine 50-75


Studies (IDS):

Mechanisms,

Methods, and

Malignancies (M3)

Small group leader:

Classification of

Neoplasms (1

session)

Medicine 10-15


10 of 27


Contribution

School Class

Size

2015 - 2016 Mechanisms,

Methods and

Malignancies (M3)

Small group leader:

Classification of

Neoplasms (1

session)

Medicine 10-15

2015 - 2016 Breast Cancer GAP

lab

Laboratory instructor Medicine ~80-

100

2016 - 2017 Breast Cancer GAP

lab


100

2016 - 2017 Prostate Cancer GAP

lab


100

2016 - 2017 Mechanisms,

Methods and

Malignancies (M3),

UCSF School of

Medicine

Small group leader:

Classification of

Neoplasms (1

session)

Medicine 10-15

INFORMAL TEACHING

2008 - 2010 Department of Pathology, Massachusetts General Hospital, Boston,

Massachusetts: Gross and microscopic pathology to rotating medical students

and junior pathology residents

2010 - 2011 Department of Pathology, University of California (UCSF), San Francisco,

California: Gross and microscopic pathology to rotating medical students


California: Gross and microscopic pathology to junior pathology residents

(including prepared slide sessions)


California: Basic liver pathology to clinical hepatology fellows at monthly "Liver

Pathology" meetings


California: Supervised laboratory work of Catherine Carbone, a post-graduate

researcher in the laboratory of Dr. Barbara Panning (Department of

Biochemistry and Biophysics)

2013 - present Department of Pathology, University of California (UCSF), San Francisco,

California: Diagnostic gross and microscopic surgical pathology to pathology

residents and fellows during daily signout, prepared slide sessions

2016 - present Department of Pathology, University of California (UCSF), San Francisco,

California: Cancer genomics using the UCSF500 targeted next-generation

sequencing panel to residents and fellows.


11 of 27

MENTORING SUMMARY Teaching and mentoring pathology residents and fellows is an important component of my practice, including diagnostic surgical pathology and pathology research projects. I also serve as an ad hoc proctor for UCSF clinical instructors in breast pathology and have mentored visiting high school students and visiting faculty from other institutions. As a research project mentor for residents and fellows, I provide guidance on project design, experimentation, data analysis and presentation, and manuscript preparation and writing. Projects have been presented by the mentees at the San Antonio Breast Cancer Symposium and United States and Canadian Academy of Pathology (USCAP) meetings, as well as local and university conferences, as poster or platform presentations. A project on TERT promoter mutations in combined hepatocellular-cholangiocarcinomas received first runner-up for the prestigious Hans Popper Best Trainee award at the 2014 USCAP meeting (Dr. Tsokos). Many of these projects have resulted in published manuscripts in top-tier pathology journals, and others are currently preparation. I serve as a faculty mentor for residents presenting at the departmental Mechanisms of Disease (MOD) conference, a core feature of our residency/fellowship curriculum at which residents and fellows biannually present a scientific/medical topic of interest to the entire department in a formal lecture format.

PREDOCTORAL STUDENTS SUPERVISED OR MENTORED

Dates Name Program or

School

Mentor Type Role Current

Position

2016 - Tianming Chu Project Mentor Summer research

project mentor

High school

student

2017 - Tianming Chu Project Mentor Summer research

project mentor

High school

student

2012 - 2013 Catherine

Carbone

Project Mentor Research project

supervisor

Graduate

student,

UCSF

POSTDOCTORAL FELLOWS AND RESIDENTS MENTORED

Dates Name Fellow Mentor Role Faculty Role Current

Position

2014 - 2017 Christos

Tsokos, MD

PhD

Anatomic

Pathology

resident and

surgical

pathology

fellow

Research/Scholarly

Mentor, Project

Mentor, Career

Mentor

Research project

mentor

Research

fellow, MGH

Pathology (R.

Kingston lab),

Boston, MA

2015 - 2017 Su-Yang Liu,

MD PhD

Anatomic

pathology

resident

Research/Scholarly

Mentor, Project

Mentor

MOD mentor and

research project

mentor

Research

fellow, UCSF


12 of 27

Dates Name Fellow Mentor Role Faculty Role Current

Position

2014 - 2017 Dianna Ng, MD Anatomy

pathology

resident

Research/Scholarly

Mentor, Project

Mentor

Project co-mentor Assistant

Professor,

UCSF/ZSFG

H

2015 - Emily Chan,

MD PhD

Anatomic

Pathology

resident

Project Mentor Project mentor

(MOD)

Clinical

instructor,

UCSF

2015 - present Gregory Bean,

MD PhD

Anatomic

Pathology

resident,

Breast and

surgical

pathology

fellow

Research/Scholarly

Mentor, Project

Mentor, Career

Mentor

MOD mentor and

research project

mentor

Assistant

Professor,

Stanford

University,

Stanford, CA

2016 - John

Cannatella, MD

Anatomic

Pathology

resident

Project Mentor Project mentor

(MOD)

Pathology

resident,

UCSF

2016 - present Eliah Shamir,

MD PhD

Anatomic

Pathology

resident,

Breast and

surgical

pathology

fellow

Research/Scholarly

Mentor, Project

Mentor

Research project

mentor and MOD

mentor

Breast and

surgical

pathology

fellow, UCSF

2017 - present Jeanette Ruiz,

MD

Anatomic

pathology

resident

Research/Scholarly

Mentor, Project

Mentor

Research project

mentor

Surgical

Pathology

fellow, UCSF

FACULTY MENTORING

Dates Name Position while

Mentored

Mentor Type Mentoring Role Current

Position

2017 - Gregory Bean,

MD PhD

Clinical

Instructor,

UCSF

Research/Scholarly

Mentor, Project

Mentor, Career

Mentor, Co-

Mentor/Clinical

Mentor

Clinical, career, and

research project

mentor

Assistant

Professor,

Stanford

VISITING FACULTY MENTORED

2014 - 2014 Cynthia Osorio, MD

(Avon Scholar)

Antonio Prudente Foundation, AC Camargo Cancer

Center, Department of Pathology, Sao Paolo, Brazil.


13 of 27

2018 - Minlin Kim Seoul National University, Bundang Hospital, Seoul,

South Korea.

RESEARCH AND CREATIVE ACTIVITIES

RESEARCH AND CREATIVE ACTIVITIES SUMMARY My overall research mission is to translate insights in cancer biology towards improvements in breast cancer diagnostics and treatment. I am especially interested in breast cancer genomics and the diagnostic integration of molecular pathology with histopathology for meaningful classification of breast tumors. In this context, I have published work on the genomics of breast secretory carcinomas and their intrinsic relationship to salivary gland analogues (Mod Pathol. 2017), the genomics of metaplastic breast carcinoma histologic subtypes (Mod Pathol. 2018), and the genetics of mucoepidermoid carcinomas (Histopathology 2018). Ongoing work in this area includes additional genotype-phenotype correlations in metaplastic breast carcinomas and molecular characterization of other salivary gland-like carcinomas, such as pleomorphic adenomas of the breast. As a member of The Cancer Genome Atlas (TCGA) breast pathology expert panel, I was involved in a recently published integrative study correlating the morphologic and molecular features of breast cancers using a variety of platforms (J Pathol. 2017). Another research interest focuses on neoplastic precursor lesions, cancer risk and tumor progression pathways. Published and ongoing work in this area includes phyllodes tumor genetics, deep sequencing of paired precursor lesions in the low grade epithelial neoplasia pathway, and the relationship of classic lobular carcinoma in situ (LCIS) with more aggressive variants and invasive breast cancer (Am. J. Surg. Pathol. 2018). I have an interest in fibroepithelial lesions and have published work on the genetics of malignant phyllodes tumors, highlighting recurrently aberrant oncogenic pathways, tumor progression and genetic heterogeneity of these rare tumors (Mod Pathol. 2016). I am collaborating with Dr. Christopher Benz (Buck Institute for Research on Aging) to elucidate the role of IGF1R polymorphisms in breast cancer risk with morphologic, immunophenotypic, and molecular correlation in benign breast tissue. In collaboration with Dr. Andrei Goga (Medicine and Tissue Biology, UCSF), I have contributed to seminal work on the role of fatty acid oxidation and metabolomics in triple negative breast cancer (Nat Med. 2016). Ongoing collaborative work with Dr. Goga’s group involves the role of lipolysis in breast cancer growth and invasion (bioRxiv 277939). I have collaborated with Drs. Laura Esserman (Surgery, UCSF) and Pamela Munster (Oncology, UCSF) in studying the role of the immune system and microenvironment in breast cancer growth and development (Breast Cancer Res Treat. 2017, Oncotarget 2017). Ongoing collaborative work with Dr. Esserman in this area involves the effects of direct Pembrolizumab injections on pathobiology and tumor-directed immune response in patients with ductal carcinoma in situ. Other collaborations include a multi-institutional study non-classical HER2 patterns in breast cancer (Mod. Pathol. 2017), studies of drug delivery approaches in breast cancer (Laura Vant Veer, Breast Cancer Res. 2017; Pamela Munster, Sci Rep. 2018), molecular mechanisms of acquired drug resistance to targeted therapies (Sourav Bandyopadhyay, Nat. Med., 2018), and transcriptomics of cancer-adjacent normal tissues (Atul Butte, Nat Commun. 2017). I am a collaborator in clinically-directed studies aimed at improving breast cancer diagnostics and treatment. I am a study pathologist for the I-SPY2 clinical trial (Dr. Laura Esserman), an adaptive multicenter effort to personalize breast neoadjuvant breast cancer treatment (N Engl J Med. 2016). I am also a member of the Athena Breast Health Network Pathology working group. A collaborative effort with this group identified intratumoral ER heterogeneity as a


14 of 27

predictive factor for an increased long-term risk of fatal breast cancer in patients enrolled in the STO-3 trial (J Natl Cancer Inst. 2018). I previously served as study pathologist in a multicenter study that aims to use novel imaging models based on lesional water, protein, and lipid composition (3CB) in diagnostic mammography to improve the specificity of breast cancer diagnosis and decrease unnecessary biopsies (Dr. John Shepherd).

RESEARCH AWARDS - CURRENT

1. I-SPY2 Trial Study pathologist 3 % effort Esserman (PI)

QuantumLeap Health Care Collaborative 01/01/2014 06/30/2020

I-SPY 2 Trial (Investigation of Serial studies to predict

your therapeutic response with imaging and molecular

analysis)

$ 1,894,595 total

The I-SPY 2 TRIAL is a Phase II, randomized, controlled, multi-center trial for women with

newly diagnosed, locally advanced breast cancer (Stage II/III). The trial employs an adaptive

design, matching experimental therapies with patients based on the use of biomarkers,

investigating whether new therapies can be added to standard chemotherapy or whether they

may replace certain components of standard chemotherapy in the neoadjuvant setting.

Therapies that are found effective can move onto a more focused Phase III registration trial.

Study pathologist, including histopathologic evaluation of pre- and post-treatment cancers,

residual cancer burden (RCB) grading, tumor evaluation for molecular testing

2. PI Krings (PI)

UCSF Department of Pathology 5/30/2017 Present

Genomic Analysis of Non-Classic Lobular Carcinoma in

Situ Variants and Synchronous Invasive Lobular

Carcinoma

$ 12,600 total

3. PI Krings (PI)


Genomic Analysis of Chondroid Matrix-Producing Breast

Carcinomas: Genotype-Phenotype Correlation

$ 11,560 total

4. PI Krings (PI)


Genomic Analysis of Basaloid Breast Carcinomas

Reveals Distinct Genetics from Other Triple Negative

Breast Cancers

$ 13,216 total


15 of 27

RESEARCH AWARDS - PAST

1. UCSF500 Cancer Gene Pilot

Program

PI Krings, Gregor

(PI)

UCSF Department of Pathology/Clinical Cancer

Genomics Laboratory

1/12/2015

Characterizing the Molecular Progression of Low-grade

Intraductal Neoplasia in the Breast

$ 16,500 total


Program

Co-PI Jen, Kuang-Yu

(PI)

UCSF Department of Pathology/Clinical Cancer Genomic

Laboratory

1/12/2015

Mutational Landscape of Bilateral Lobular Carcinomas $ 13,000 total


Program

Co-PI Ferrell, L. (PI)

UCSF Department of Pathology/Clinical Cancer Genomic

Laboratory

1/12/2015

Genomic analysis of combined hepatocellular-

cholangiocarcinoma

$ 11,000 total


Program

Co-PI Vohra, P. (PI)


Genomics Laboratory

1/12/2015

Genomic characterization of metaplastic carcinomas of

the breast

$ 16,500 total


Program

Co-PI Chen, Y-Y (PI)


Genomics Laboratory

1/12/2015

Genomic evolution of metastatic progression in breast

cancer

$ 16,500 total

6. 5RO1CA166945-03 Study pathologist 10 % effort Shepherd (PI)


16 of 27

National Institutes of Health 3/6/2013 2/28/2018

Lesion Composition and Qualitative Imaging Analysis on

Breast Cancer

This project aims to use novel imaging models based on lesional water, protein, and lipid

composition (3CB) in diagnostic mammography to improve the specificity of breast cancer

diagnosis and decrease unnecessary biopsies.

Provide all pathology support and expertise for the project.

PEER REVIEWED PUBLICATIONS

1. Virella G., Koskinen S., Krings G., Onorato J.M., Thorpe S.R., and Lopes-Virella M. Immunochemical characterization of purified human oxidized low-density lipoprotein antibodies. Clin. Immunol. 2000;95: 135-144. PMID: 10779407

2. Vielma, S.A., Krings, G., and Lopes-Virella, M.F. Chlamydophila pneumoniae induces ICAM-1 expression in human aortic endothelial cells via protein kinase C-dependent activation of nuclear factor-kappaB. Circ. Res. 2003; 92:1130-1137.PMID: 12714566

3. Krings, G. and Bastia, D. swi1- and swi3-dependent and independent replication fork arrest at the ribosomal DNA of Schizosaccharomyces pombe. Proc. Natl. Acad. Sci. U.S.A. 2004; 101: 14085-14090. PMID: 15371597

4. Krings, G. and Bastia, D. Sap1p binds to Ter1 at the ribosomal DNA of Schizosaccharomyces pombe and causes polar replication fork arrest. J. Biol. Chem. 2005;280:39135-39142. PMID: 16195226

5. Krings, G. and Bastia, D. Molecular architecture of a eukaryotic DNA terminus-terminator protein complex. Mol. Cell. Biol. 2006;26:8061-8074. PMID: 16940176

6. Bastia, D., Zzaman S., Krings, G., Saxena, M., Peng, X., and Greenberg, M.M. Replication termination mechanism as revealed by Tus-mediated polar arrest of a sliding helicase. Proc. Natl. Acad. Sci. U.S.A. 2008;105:12831-12836. PMID: 18708526

7. Vagefi, P.A., Stangenberg, L., Krings, G., Forcione, D.G., Fernandez-del Castillo, C., and Wargo, J.A. Ocular melanoma metastatic to the pancreas following a 28 year disease-free interval. Surgery 2010;148:151-154.PMID: 19744448

8. Krings, G., Ramachandran, R, Jain, D., Wu, T.-T., Yeh, M.W., Torbenson, M., and Kakar, S. (2013) Immunohistochemical pitfalls and the importance of glypican 3 and arginase in the diagnosis of scirrhous hepatocellular carcinoma. Modern Pathology 2013;26:782-791. PMID: 23348905

9. Krings, G.*†, Can, B.*, and Ferrell, L. Aberrant Centrizonal Features in Chronic Hepatic Venous Outflow Obstruction: Centrilobular Mimicry of Portal-based Disease. Am. J. Surg. Pathol. 2014; 38(2):205-214. PMID: 24418854 *Co-first authors, †Corresponding author

10. Krings, G.*, Nystrom, M., Mehdi, I., Vohra, P., and Chen, Y-Y. Diagnostic Utility and Sensitivities of GATA3 Antibodies in Triple Negative Breast Cancer. Hum Pathol 2014;45(11):2225-32. PMID: 25150746 *Corresponding author

11. Moh, M., Krings, G., Ates, D., Aysal, A., Kim, G.E. and Rabban, J.T. SATB2 Expression Distinguishes Ovarian Metastases of Colorectal and Appendiceal Origin From Primary Ovarian Tumors of Mucinous or Endometrioid Type. Am J Surg Pathol. 2016 Mar;40(3):419-32. PMID: 26551622


17 of 27

12. McKelvie, P.A., Climent, F., Krings, G., Hasserjian, R.P., Abramson, J.S., Pilch, B.Z., Harris, N.L., Ferry, J.A., Zukerberg, L.R., and Sohani, A.R. Small-cell predominant extranodal NK/T-cell lymphoma, nasal type: Clinicopathologic analysis of a series of cases diagnosed in a Western population. Histopathology. 2016 Oct;69(4):667-79. PMID: 27144366

13. Camarda, R., Zhou, A.Y., Kohnz, R.A., Balakrishnan, S., Mahieu, C., Anderton, B., Eyob, H., Kajimura, S., Tward, A., Krings, G., Nomura, D.K., and Goga, A. Inhibition of fatty acid oxidation as a therapy for MYC-overexpressing triple-negative breast cancer. Nat Med. 2016 Apr;22(4):427-32. PMID: 26950360

14. Myers, S.A., Peddada, S., Chatterjee, N., Freidreich, T., Tomoda, K., Krings, G., Thomas, S., Broeker, M. Maynard, J., Thomson, M, Pollard, K., Yamanaka, S., Burlingame, A.L., and Panning, B. SOX2 O-GlcNAcylation alters its protein-protein interactions and genomic occupancy to modulate gene expression in pluripotent cells. Elife. 2016 Mar 7;5:e10647. doi: 10.7554/eLife.10647. PMID: 26949256

15. Liu, S-Y., Joseph, N.M., Ravindranathan, A., Stohr, B., Greenland, N., Vohra, P., Hosfield, E., Yeh, I., Talevich, E., Onodera, C., Van Ziffle, J., Grenert, J.P., Bastian, B., 4, Chen, Y-Y., and Krings, G*. Genomic Profiling of Malignant Phyllodes Tumors Reveals Aberrations in FGFR1 and PI-3 Kinase/RAS Signaling Pathways and Provides Insights into Intratumoral Heterogeneity. Mod Pathol. 2016 Sep;29(9):1012-27. PMID: 27255162 *Corresponding author

16. Tsokos, C.G., Krings, G., Yilmaz, F., Ferrell, L.D., and Gill, R.M. Proliferative Index Facilitates Distinction Between Benign Biliary Lesions and Intrahepatic Cholangiocarcinoma. Hum Pathol. 2016 Nov;57:61-67. PMID: 27396933

17. Rugo HS, Olopade OI, DeMichele A, Yau C, van 't Veer LJ, Buxton MB, Hogarth M, Hylton NM, Paoloni M, Perlmutter J, Symmans WF, Yee D, Chien AJ, Wallace AM, Kaplan HG, Boughey JC, Haddad TC, Albain KS, Liu MC, Isaacs C, Khan QJ, Lang JE, Viscusi RK, Pusztai L, Moulder SL, Chui SY, Kemmer KA, Elias AD, Edmiston KK, Euhus DM, Haley BB, Nanda R, Northfelt DW, Tripathy D, Wood WC, Ewing C, Schwab R, Lyandres J, Davis SE, Hirst GL, Sanil A, Berry DA, Esserman LJ; I-SPY 2 Investigators. Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer. N Engl J Med. 2016 Jul 7;375(1):23-34.PMID: 27406347

18. Park JW, Liu MC, Yee D, Yau C, van 't Veer LJ, Symmans WF, Paoloni M, Perlmutter J, Hylton NM, Hogarth M, DeMichele A, Buxton MB, Chien AJ, Wallace AM, Boughey JC, Haddad TC, Chui SY, Kemmer KA, Kaplan HG, Isaacs C, Nanda R, Tripathy D, Albain KS, Edmiston KK, Elias AD, Northfelt DW, Pusztai L, Moulder SL, Lang JE, Viscusi RK, Euhus DM, Haley BB, Khan QJ, Wood WC, Melisko M, Schwab R, Helsten T, Lyandres J, Davis SE, Hirst GL, Sanil A, Esserman LJ, Berry DA; I-SPY 2 Investigators. Adaptive Randomization of Neratinib in Early Breast Cancer. N Engl J Med. 2016 Jul 7;375(1):11-22. PMID: 27406346

19. Ballard M, Jalikis F, Krings G, Schmidt RA, Chen YY, Rendi MH, Dintzis SM, Jensen KC, West RB, Sibley RK, Troxell ML, Allison KH. 'Non-classical' HER2 FISH results in breast cancer: a multi-institutional study. Mod Pathol. 2017 Feb;30(2):227-235. PMID: 27739440

20. Campbell MJ, Baehner F, O'Meara T, Ojukwu E, Han B, Mukhtar R, Tandon V, Endicott M, Zhu Z, Wong J, Krings G, Au A, Gray JW, Esserman L. Characterizing the immune microenvironment in high-risk ductal carcinoma in situ of the breast. Breast Cancer Res Treat. 2017 Jan;161(1):17-28. PMID: 27785654


18 of 27

21. Heng YJ, Lester SC, Tse GMK, Factor RE, Allison KH, Collins LC, Chen Y-Y, Jensen KC, Johnson NB, Jeong JC, Punjabi R, Shin SJ, Singh K, Krings G, Eberhard DA, Tan PH, Korski K, Waldman F, Gutman DA, Sanders M, Reis-Filho JS, Flanagan SR, Gendoo DM, Chen G, Kains BH, Ciriello G, Hoadley KA, Perou CM, and Beck AH. The molecular basis of breast cancer pathologic phenotypes. J Pathol. 2017 Feb;241(3):375-391. PMID: 27861902

22. Krings, G.*, Joseph, N., Bean, G., Solomon, D., Onodera, C., Talevich, E., Yeh, I., Grenert, J.P., Hosfield, E., Crawford, E.D., Jordan, R.C., van Zante, A., Zaloudek, C.Z., Shin, S.J., and Chen, Y-Y. Genomic Profiling of Breast Secretory Carcinomas Reveals Distinct Genetics from Other Breast Cancers and Similarity to Mammary Analogue Secretory Carcinomas. Mod Pathol. 2017 Aug;30(8):1086-1099. doi: 10.1038/modpathol.2017.32. Epub 2017 May 26. PMID: 28548128 *Corresponding author

23. Bartelink, I.H., Prideaux, B., Krings, G., Wilmes, L., Lee, E.P.R., Pan, B., Hann, B., Coppe, J.P., Heditsian, D., Swigart-Brown, L., Jones, E.F., Magnitsky, S., Keizer, R., deVries, N., Rosing, H., Pawlowska, N., Thomas, S., Dhawan, M., Aggarwal, R., Munster, P.N., Esserman, L.J., Ruan, W., Wu, A.H.B., Yee, D., Dartois,V., Savic, R.M., Wolf, D.M., and vant Veer, L. Heterogeneous Drug Penetrance of Veliparib and Carboplatin Measured in Triple Negative Breast Tumors. Breast Cancer Res. 2017 Sep 11; 19(1):107. PMID: 28893315

24. Aran, D., Camarda, R., Odegaard, J., Paik, H., Oskotsky, B., Krings, G., Goga, A., Sirota, M., and Butte, A.J. Comprehensive Analysis of Normal Adjacent to Tumor Transcriptomes. Nat Commun. 2017 Oct 20;8(1):1077.PMID: 29057876

25. Terranova-Barberio M., Thomas, S. Ali, N., Pawlowska, N., Park, J., Krings, G., Rosenblum, M.D., Budillon, A., and Munster, P.N. HDAC inhibition potentiates immunotherapy in triple negative breast cancer. Oncotarget. 2017 Dec 12;8(69):114156-114172. PMID: 29371976

26. Park, J., Thomas, S., Zhong, A.Y., Wolfe, A.R., Krings, G., Terranova-Barberio. M., Pawlowska, N., Benet, L.Z., and Munster, P.N.Local delivery of hormonal therapy with silastic tubing for prevention and treatment of breast cancer. Sci Rep. 2018 Jan 8;8(1):92. PMID: 29311658

27. Lindstrom, L.S., Yau, C., Czene, K., Thompson, C.K., Hoadley, K.A., van’ t Veer, L.J.,

Balassanian, R., Bishop, J.W., Carpenter, P.M., Chen, Y-Y., Datnow, B., Hasteh, F.,

Krings, G., Lin, F., Zhang, Y., Nordenskjold, B., Sta l, O., Benz, C.C., Fornander, T.,

Borowsky, A.D., Esserman, L.J.; for the STO Trialists Group.Intratumor Heterogeneity of the Estrogen Receptor and the Long-term Risk of Fatal Breast Cancer. J Natl Cancer Inst. 2018 Jan 19. doi: 10.1093/jnci/djx270. [Epub ahead of print] PMID: 29361175

28. Cohen, J., Sabnis, A.J., Krings, G., Cho, S.-J., Horvai, A.E., and Davis, J.D. EWSR1-NFATC2 Gene Fusion in a Soft Tissue Tumor with Epithelioid Round Cell Morphology and Abundant Stroma: A Case Report and Review of the Literature. Hum Pathol. 2018 Apr 4. pii: S0046-8177(18)30097-2. PMID: 29626598

29. Krings, G.* and Chen, Y-Y. Genomic Profiling of Metaplastic Breast Carcinomas Reveals Genetic Heterogeneity and Relationship to Ductal Carcinoma. Mod Pathol. 2018 Jun 26. doi: 10.1038/s41379-018-0081-z. [Epub ahead of print] PMID: 29946183 *Corresponding author (Journal cover, November 2018)


19 of 27

30. Shamir, E.R., Devine, W.P., Umetsu, S.E., Krings, G., Federman, S., Cho, S.-J., Saunders, T.A., Jen, K.-Y., Bergsland, E., Jones, K., Kim, G.E., Kakar, S., Chiu, C.Y., and Joseph, N.M. Identification of high-risk human papillomavirus and Rb/E2F pathway genomic alterations in mutually exclusive subsets of colorectal neuroendocrine carcinoma. Mod Pathol 2018 Sep 20. doi: 10.1038/s41379-018-0131-6. [Epub ahead of print] PMID: 30237525

31. Bean, G.R., Anderson, J., Sangoi, A.R., Krings, G.*, and Garg, K.* DICER1 mutations are frequent in müllerian adenosarcomas and are independent of rhabdomyosarcomatous differentiation. Mod Pathol. 2018 Sep 28. doi: 10.1038/s41379-018-0132-5. [Epub ahead of print] PMID: 30380176 *co-senior author

32. Bean, G.R., Krings, G., Otis, C.N., Solomon, D.A., García, J.J., van Zante, A., Camelo-Piragua, S., Van Ziffle, J., Chen, Y-Y. CRTC1-MAML2 Fusion in Mucoepidermoid Carcinoma of the Breast. Histopathology. 2018 Oct 31. doi: 10.1111/his.13779. [Epub ahead of print] PMID: 30380176

33. Shah, K.N., Bhatt, R., Rotow, J., Rohrberg. J., Olivas, V., Wang, V.E., Hemmati, G., Martins, M.M., Maynard, A., Kuhn, J., Galeas, J., Donnella, H.J., Kaushik, S., Ku, A., Dumont, S., Krings, G., Haringsma, H.J., Robillard, L., Simmons, A.D.,Harding, T.C., McCormick, F., Goga, A., Blakely, C.M., Bivona, T.G., and Bandyopadhyay, S. Aurora kinase A drives the evolution of resistance to third generation EGFR inhibitors in lung cancer. Nat Med. 2018 Nov 26. doi: 10.1038/s41591-018-0264-7. [Epub ahead of print] PMID: 30478424

34. Shamir, E.R., Chen, Y-Y., Chu, T., Pekmezci, M., Rabban, J.R., and Krings, G.* Pleomorphic and Florid Lobular Carcinoma in Situ Variants of the Breast: A Clinicopathologic Study of 85 Cases With and Without Invasive Carcinoma from a Single Academic Center. Am J Surg Pathol. 2018 Nov 27. doi: 10.1097/PAS.0000000000001191. [Epub ahead of print] PMID: 30489319 *Corresponding author

35. Joseph, N.M., Tsokos, C.G., Umetsu, S.E., Shain, A.H., Kelley, R.K., Onodera, C., Bowman, S., Talevich, E., Ferrell, L.D., Kakar, S., Krings, G. Genomic profiling of combined hepatocellular-cholangiocarcinoma reveals similar genetics to hepatocellular carcinoma. J Pathol. 2019 Jan 28. doi: 10.1002/path.5243. [Epub ahead of print] PMID: 30690729

REVIEW ARTICLES

1. Krings, G., Bean, G.R., and Chen, Y-Y. Fibroepithelial Lesions - The WHO Spectrum. Semin Diagn Pathol. 2017 Sep;34(5):438-452. doi: 10.1053/j.semdp.2017.05.006. Epub 2017 May 28. Invited review. PMID: 28688536

2. Krings, G., McIntire, P., and Shin, S.J. Myofibroblastic, Fibroblastic, and Myoid Lesions of the Breast. Semin Diagn Pathol. 2017 Sep;34(5):427-437. doi: 10.1053/j.semdp.2017.05.010. Epub 2017 May 28. Invited review. PMID: 28751104

BOOKS AND CHAPTERS

1. Krings, G. and Chen, Y-Y. (2016). Fibroepithelial Lesions. In Shin, S (Ed.), Comprehensive Guide to Core Needle Biopsies of the Breast. New York, NY: Springer.

2. Vohra, P., Krings, G., and Chen, Y-Y. (2016). Less Common Triple Negative Breast Cancers. In Shin, S (Ed.), Comprehensive Guide to Core Needle Biopsies of the Breast. New York, NY: Springer.


20 of 27

3. Krings, G., Rabban, J.T., and Shin, S.J. (2016). Mesenchymal Neoplasms of the Breast, In Dabbs, DJ (Ed.), Breast Pathology (2nd edition). Expert Consult series. Philadelphia, PA: Elsevier.

4. Krings, G., Sorenson, P., Yang, W., Chen, Y-Y. Secretory Carcinoma, In WHO Classification of Tumours of the Breast (5th edition). Lyon, France: IARC. (in preparation, invited author)

CONFERENCE ABSTRACTS

1. Vielma, S.A., Krings, G., and Lopes-Virella, M.F. Protein Kinase C and Nuclear Factor-Kappa B signaling pathways mediate the upregulation of Intracellular Adhesion Molecule-1 induced by Chlamydophila pneumonia. Arterioscler Thromb Vasc Biol. 2003;23(5):a22, Abstract P121.

2. Sohani, A. R., Krings, G., Hasserjian, R.P., Pilch, B.Z., Harris, N.L., and Ferry, J.A. Extranodal NK/T-cell lymphoma nasal type with a predominance of small cells: Challenging diagnosis of a putative early lesion. European Association of Haematopathology (EAHP), 15th Annual Meeting, Uppsala, Sweden, 2010. [Poster]

3. Krings, G., Jain, D., Wu, T-T., Yeh, M., Torbenson, M., and Kakar, S. Immunohistochemical pitfalls and the importance of glypican-3 in the diagnosis of scirrhous hepatocellular carcinoma. Modern Pathology 2011;24 (suppl 1): 366A, Abstract #1553. Presented at United States and Canadian Academy of Pathology (USCAP), 100th Annual Meeting, San Antonio, Texas, 2011. [Poster]

4. Das, K., Krings, G., Pitman, M., and Mino-Kenudson, M. A novel monoclonal antibody, mAb Das-1, identifies a colonic phenotype and is specific for intraductal papillary mucinous neoplasm (IPMN) with a high risk for malignant transformation. Modern Pathology 2011;24 (suppl 1): 358A, Abstract #1519. Presented at United States and Canadian Academy of Pathology (USCAP), 100th Annual Meeting, San Antonio, Texas, 2011. [Poster]

5. Krings, G., Jain, D., Wu, T-T., Yeh, M., Torbenson, M., and Kakar, S. Immunohistochemical pitfalls and the importance of glypican-3 in the diagnosis of scirrhous hepatocellular carcinoma. Presented at UCSF Liver Center Symposium, March 11th, 2011, San Francisco, California. [Poster]

6. Krings, G., Ferrell, L., and Gill, R. Ki-67 and p53 expression as an immunohistochemical tool in the differential diagnosis of benign and malignant biliary lesions. Modern Pathology 2012;25 (supp 2): 416A, Abstract #1738. Presented at United States and Canadian Academy of Pathology (USCAP), 101st Annual Meeting, Vancouver, British Columbia, 2012. [Poster]<<<<

7. Can, B., Krings, G., and Ferrell, L. Arterialization and ductular metaplasia of centrizonal scars in chronic venous outflow obstruction: a frequently misinterpreted lesion. Modern Pathology 2012;25 (supp 2): 412A, Abstract #1720. Presented at United States and Canadian Academy of Pathology (USCAP), 101st Annual Meeting, Vancouver, British Columbia, 2012. [Poster]

8. Krings, G., Ferrell, L.F., and Gill, R.M. Ki-67 and p53 Expression as an Immunohistochemical Tool in the Differential Diagnosis of Benign and Malignant Biliary Lesions. Presented at UCSF Liver Center Symposium, June 15th, 2012, San Francisco, California. [Poster]


21 of 27

9. Krings, G., Can, B., and Ferrell, L.F. Altered hepatic vascular and lobular organization near centrizonal scars in chronic venous outflow obstruction. Modern Pathology 2013;26 (supp 2s): 405A, Abstract #1692. Presented at United States and Canadian Academy of Pathology (USCAP), 102nd Annual Meeting, Baltimore, Maryland, 2013. [Poster]

10. Krings, G., Can, B., and Ferrell, L.F. Altered hepatic vascular and lobular organization near centrizonal scars in chronic venous outflow obstruction. Presented at UCSF Liver Center Symposium, April 12th, 2013, San Francisco, California. [Poster]

11. Mori, M., Krings, G., Chan, L., Wolf, D., Chen, Y-Y., Kerlikowske, K., Tlsty, T.D., Coppe, J-P., Matsuda, N., Suzuki, K., Nakamura, S., and van't Veer, L. Predictive biomarkers for invasion on final pathology in patients with preoperative diagnosis of ductal carcinoma in situ of the breast by needle biopsy. Presented at San Antonio Breast Cancer Symposium, San Antonio, Texas, 2013. [Poster]

12. Krings, G., Nystrom, M., Vohra, P., and Chen, Y-Y. Sensitivity and Utility of Commonly Used GATA3 Antibodies in Triple Negative Breast Cancers. Modern Pathology 2014;27 (supp 2): 61A, Abstract #235. Presented at United States and Canadian Academy of Pathology (UCSAP), 103rd Annual Meeting, San Diego, California, 2014. [Poster]

13. Firetag, B., Krings, G., Nystrom, M.J., Berry, A.B., Chen, Y-Y., and Balassanian, R. Aberrant Staining for Mesothelial Markers Calretinin and WT-1 in Triple Negative Breast Cancers. Modern Pathology 2014;27 (supp 2): 102A, Abstract #407. Presented at United States and Canadian Academy of Pathology (USCAP), 103rd Annual Meeting, San Diego, California, 2014. [Poster]

14. Mori, M., Krings, G., Chan, L., Wolf, D., Chen, Y-Y., Kerlikowske, K., Tlsty, T.D., Coppe, J-P., Matsuda, N., Suzuki, K., Nakamura, S., and van’t Veer, L. Predictive biomarkers of invasive carcinoma on excision in patients with a diagnosis of ductal carcinoma in situ of the breast by needle biopsy. J Clin Oncol 32, 2014 (suppl; abstr e12029).

15. Drukker K., Malkov S., Giger M., Joe B., Kerlikowske K., Drukteinis J., Wisner D., Pereira M., Kazemi L., Krings G., Patel B., and Shepherd J. Three-Compartment Breast Imaging and Quantitative Mammographic Image Analysis: Synergy for Improved Diagnosis. Radiological Society of North America 2014 Scientific Assembly and Annual Meeting, Chicago IL. November 30th-December 5th. [Poster]

16. Bartelink, I.H., Prideau,x B., Hann, B., Krings, G., Coppe, J.P., Swigart-Brown, L., Lee, PRE, Esserman, L., Yee, D., Wolf, D., Savic, R.M., and van't Veer, L. Spatial distribution of veliparib measured by matrix assisted laser desorption ionization mass spectrometry in triple negative breast cancer tumors. Cancer Research 05/2015; 75(9 Supplement):P6-11-02-P6-11-02. J Clin Oncol 32, 2014 (suppl 26; abstr 161).Presented at San Antonio Breast Cancer Symposium, San Antonio, Texas, December 9th-13th, 2014 [Poster, P6-11-02].

17. Ng, D., Krings, G., Yau, C., White, K., Hou, J., Chua, A., Grenert, J.P., Chen, Y-Y. Alterations in HER2 status and outcome following neoadjuvant chemotherapy in HER2-positive breast cancer. Cancer Research 05/2015; 75(9 Supplement):P3-06-28-P3-06-28. Presented at San Antonio Breast Cancer Symposium, San Antonio, Texas, December 9th-13th, 2014. [Poster, P3-06-28]

18. Tsokos, C., Liu, X., Solomon, D., Chen, X., Hale, G., Seeley, E.S., Kakar, S., and Krings, G. Telomerase Reverse Transcriptase Promoter Mutations (mTERTp) in Combined Hepatocellular(HCC)-Cholangiocarcinoma(CC; cHCC-CC) Support Clonal and HCC-like


22 of 27

Origin for Both Components. Modern Pathology 2015;28(supp 2): 425A, Abstract #1697. Presented at United States and Canadian Academy of Pathology (USCAP), 104th Annual Meeting, Boston, Massachusetts, 2015. [Poster] Hans Popper Hepatopathology Society Best Trainee Abstract Award, runner-up.

19. Krings, G., Ng, D., Hou, J., Chua, A., Grenert, J.P., Chen, Y-Y. Immunophenotypic Switching of Biomarkers (IS) in Breast Cancer (BC) After Neoadjuvant Chemotherapy (NCT). Modern Pathology 2015;28(supp 2): 52A, Abstract #196. Presented at United States and Canadian Academy of Pathology (USCAP), 104th Annual Meeting, Boston, Massachusetts, 2015. [Poster]

20. Krings, G. and Chen, Y-Y. Diagnostic Sensitivity and Utility of GATA3 in Breast Cancer (BC) After Hormonal (HT) and Chemotherapy (CT). Modern Pathology 2015;28(supp 2): 52A, Abstract #195. Presented at United States and Canadian Academy of Pathology (USCAP), 104th Annual Meeting, Boston, Massachusetts, 2015. [Poster]

21. Krings, G. and Chen, Y-Y. SATB2 Expression in Metaplastic Carcinoma of the Breast (MCB) with Osseous Differentiation (OD). Modern Pathology 2015;28(supp 2): 52A, Abstract #197. Presented at United States and Canadian Academy of Pathology (USCAP), 104th Annual Meeting, Boston, Massachusetts, 2015. [Poster]

22. Ballard, M., Jalikis, F.G, Krings, G., Schmidt, R., Chen, Y-Y., Rendi, M.H., Dintzis, S.M., Jensen, K.C., West, R., Sibley, R., and Allison, K.H. Characterization of Breast Cancers with Equivocal and Non-Classical HER2 FISH Results; A Multi-Institutional Study. Modern Pathology 2015;28(supp 2): 35A, Abstract #128. Presented at United States and Canadian Academy of Pathology (USCAP), 104th Annual Meeting, Boston, Massachusetts, 2015. [Platform]

23. O'Meara, T., Campbell, M.J., Mukhtar, R., Obi-Okoye, E., Han, B., Tandon, V., Zheng, S., Zhu, Z., Endicott, M., Wicha, M., Lindstrom, L., Krings, G., Au, A., Baehner, F., Gray, J., and Esserman, L. Characterizing the Tumor Immune MicroEnvironment (TIME) in high-risk ductal carcinoma in situ. Presented at UCSF Breast Oncology Program Scientific Retreat, 2015 [Poster]

24. Brown Swigart, L., Glenn, P., Ma, A. A., Dean, L. Etzel, K., Griffin, L., Sheshadri, V., Dargis, B., Santos, C., Au, A., Balassanian, R., Chen, Y.-Y., Krings, G., Esserman, L., and van 't Veer, L.The I-SPY 2 TRIAL: Serial sample collection for biomarker studies and early identification of non-reponders. Presented at UCSF Breast Oncology Program Scientific Retreat, 2015 [Poster]

25. Bartelink, I.H., Prideaux, B., Krings, G., Wilmes, L., Lee, P.R.E.,Hann, B., Coppé, J.-P., Heditsian, D., Swigart-Brown, L., Jones, E.F., Magnitsky, S., Keizer, R., Esserman, L., Ruan, W., Wu, A., Yee, D., Dartois, V., Wolf, D., Savic, S., and VantVeer, L. Non-homogeneous drug penetrance of veliparib measured in triple negative breast tumors. Mol Cancer Ther December 2015 14; C61. Presented at American Association for Cancer Research (AACR)-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Boston, MA, November 2015. [Poster]

26. Goga, A., Camarda, R., Zhou, A.Y., Kohnz, R.A., Balakrishnan, S., Anderton, B., Mahieu, C., Eyob, H., Krings, G., and Nomura, D.K. Inhibition of fatty-acid oxidation as a therapy for triple-negative breast cancer. Cancer Res February 15, 2016 76; PD3-05. Presented at 38th Annual CTRC-AACR San Antonio Breast Cancer Symposium; December 8-12, 2015; San Antonio, TX


23 of 27

27. Drukker, K., Malkov, S., Avila, J., Kerlikowske, K., Joe, B., Krings, G., Creasman, J., Drukteinis, J., Pereira, M. M., Kazemi, L., Shepherd, J., and Giger, M.L. Identification, segmentation, and characterization of microcalcifications on mammography. Accepted for presentation at SPIE Medical Imaging, San Diego, CA, 2016.

28. Camarda, R., Zhou, A.Y., Kohnz, R.A., Balakrishnan, S., Anderton, B., Mahieu, C., Eyob, H., Tward, A., Krings, G., Nomura, D.K., and Goga, A. Inhibition of fatty acid oxidation as a therapy for MYC-overexpressing triple-negative breast cancer. Presented at UCSF Breast Oncology Program Scientific Retreat, San Francisco, CA, 2016. [Poster]

29. Bartelink. I.H., Prideaux, B., Krings, G., Wilmes, L., Lee, P.R., Hann, B., Coppé, J., Heditsian, D., Swigart-Brown, L., Jones, E.F., Magnitsky, S., Keizer, R., Esserman, L., Ruan, W., Wu, A., Yee, D., Dartois, V., Wolf, D., Savic, R., and Vant Veer, L. Nonhomogenous drug penetrance of Veliparib measured in triple negative breast tumors. Clin Pharmacol Therapeut 2016;99(Supp S1):S5–S107. Presented at the ASCPT 2016 Annual Meeting & Quantitative Translational Approaches in Oncology Pre-Conference, San Diego, CA, March 8th 2016.

30. Vohra, P., Krings, G., Vohra, M., and Chen, Y.-Y. Correlation of OncotypeDx Recurrence Score with IHC3/IHC4 and Grade in Ductal Carcinoma in Situ (DCIS). Modern Pathology 2016;29(supp 2):76A, Abstract #299. Presented at United States and Canadian Academy of Pathology (USCAP), 105th Annual Meeting, Seattle, WA, 2016. [Poster]

31. Borowsky, A., Lindstrom, L.S., Thompson, C. K., Balassanian, R., Yau, C., Chen, Y.-Y., Krings, G., Nordenskjold, B., Stal, O., Fornander, T., Esserman, L., Vant Veer, L. Phenotype and Immunophenotype Analysis of Gene Expression Defined "Indolent Risk" Breast Cancers. Modern Pathology 2016;29(supp 2):33A, Abstract #122. Presented at United States and Canadian Academy of Pathology (USCAP), 105th Annual Meeting, Seattle, WA, 2016. [Platform]

32. Borowsky, A., Balassanian, R., Chen, Y-Y., Krings, G., Zhang, Y., Carpenter, P., Bishop, J., Datnow, B., Hosteh, F., Rellatak, H., Engleberg, J., Cardiff, R., Lindstrom, L., Thompson, C., Yau, C. Interobserver Agreement of Breast Cancer Quantitative IHC Measured After “Score the Core” Training. Modern Pathology 2016;29(supp 2):33A, Abstract #121. Presented at at United States and Canadian Academy of Pathology (USCAP), 105th Annual Meeting, Seattle, WA, 2016. [Poster]

33. Ladwig, N., Joseph, N., Zaloudek, C., Rabban, J., Krings, G., and Garg, K. Molecular characterization of high grade endometrial stromal sarcoma. Modern Pathology 2016;29(supp 2):293A, Abstract #1165. Presented at United States and Canadian Academy of Pathology (USCAP), 105th Annual Meeting, Seattle, WA, 2016. [Poster]

34. Liu, S.-Y., Joseph, N., Chen, Y.-Y., Vohra, P., and Krings, G. Analysis of Malignant Phyllodes Tumor Genomic Landscape Using Capture-based Next Generation Sequencing. Modern Pathology 2016;29(supp 2):55A, Abstract #213. Presented at United States and Canadian Academy of Pathology (USCAP), 105th Annual Meeting, Seattle, WA, 2016 [Poster]

35. Liu, S.-Y., Chen, Y.-Y., Joseph, N., Vohra, P., and Krings, G. Analysis of MED12 and TERT Promoter Mutations in Fibroepithelial Lesions, Metaplastic Carcinomas and Spindle Cell Lesions of the Breast. Modern Pathology 2016;29(supp 2):55A, Abstract #214. Presented at United States and Canadian Academy of Pathology (USCAP), 105th Annual Meeting, Seattle, WA, 2016. [Poster]<<


24 of 27

36. Krings, G., Joseph, N.M., Bean, G.R., Onodera, C., Talevich, E., Yeh, I., Jordan, R., Grenert, J.P., Hosfield, E., Zaloudek, C., Van Zante, A., Shin, S.J., and Chen, Y-Y. Genomic Profiling of Secretory Carcinoma. Presented at United States and Canadian Academy of Pathology (USCAP), 106th Annual Meeting, San Antonio, 2017. [Platform]

37. Krings, G., Chen, Y-Y., and Jen, K-Y. Genomic Profiling of Synchronous Bilateral Lobular Carcinoma. Presented at United States and Canadian Academy of Pathology (USCAP), 106th Annual Meeting, San Antonio, 2017. [Poster]

38. Shamir, E., Chu, T., Rabban, J.T., Chen, Y-Y., and Krings, G. Clinicopathologic Review of Non-Classic Lobular Carcinoma In Situ Variants at a Single Academic Center. Presented at United States and Canadian Academy of Pathology (USCAP), 106th Annual Meeting, San Antonio, 2017. [Platform]

39. Ruiz, J., Krings, G. and Chen, Y-Y. Genomic Profiling of Apocrine Carcinoma of the Breast. Presented at United States and Canadian Academy of Pathology (USCAP), 106th Annual Meeting, San Antonio, 2017. [Platform]

40. Bean, G.R., Pekmezci, M., Chen, Y-Y., Hwang, E.S., and Krings, G. H3K27me3 Expression and X Chromosome Inactivation in Breast Carcinoma. Presented at United States and Canadian Academy of Pathology (USCAP), 106th Annual Meeting, San Antonio, 2017. [Poster]

41. Han, L. Chen, Y-Y., Krings, G., Mak, J., and Rabban, J.T. Occult Malignancy in Risk Reduction Bilateral Mastectomies from Women with BRCA1 or BRCA2 Germline/> Mutation: Correlation with Imaging Abnormalities and Implications for Specimen Sampling Strategies. Presented at United States and Canadian Academy of Pathology (USCAP), 106th Annual Meeting, San Antonio, 2017. [Poster]

42. Bean, G.R., Krings, G., and Garg, K. DICER1 Mutations in Müllerian Adenosarcomas. Presented at United States and Canadian Academy of Pathology (USCAP), 106th Annual Meeting, San Antonio, 2017. [Poster]

43. Cohen J., Bowman, S., Szabo, G., Umetsu, S.E., Krings, G., and Laszik, Z. Discordant Expression of cMYC and PD-L1 in Various Human Tumors. Presented at United States and Canadian Academy of Pathology (USCAP), 106th Annual Meeting, San Antonio, 2017. [Poster]

44. Korn, W.M., Yeh, I., Van Ziffle, J., Grenert, J.P., Joseph, N., Solomon, D., Laurance, A., Talevich, E., Onodera, C., Krings, G., Stohr, B.A., Blanco, A., and Bastian, B.C. Targeted next-generation DNA sequencing of paired tumor and normal DNA to reveal frequent actionable germline alterations. American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL, June 3rd, 2017. [Poster] J. Clin Oncol. 35(15): Abstract 11575.

45. Greenwood, H. Joe, B., Niell, B., Creasman, J., Giger, M., Drukker, K., Malkov, S., Kerlikowske, K., Drukteinis, J., Krings, G., and Shepherd, J. Use of three-compartment dual energy mammography in reducing false positive breast biopsies. Accepted for presentation at Radiological Society of North America Meeting, Chicago IL, 2017. [Poster]

46. Benz, C., Yau, C., Benz, S., Krings, G., Powell, M. Normal breast biopsies reveal an "active" transcriptome associating with higher breast cancer risk (Gail) scores and increased IGF1 growth factor expression. San Antonio Breast Cancer Symposium, San Antonio, Texas, 2017 [Poster] Cancer Research 78(4 Supplement):P3-10-05-P3-10-05 · February 2018 DOI: 10.1158/1538-7445.SABCS17-P3-10-05


25 of 27

47. Yee, D., DeMichele, A., Isaacs, C., Symmans, F., Yau, C., Albain, K.S., Hylton, N.M., Forero-Torres, A., Van't Veer, L.J., Perlmutter, J., Rugo, H.S., Melisko, M., Chen, Y.-Y., Balassanian, R., Krings, G.,... Esserman, L.J. Pathological complete response predicts event-free and distant disease-free survival in the I-SPY2 TRIAL. Abstract #700078. San Antonio Breast Cancer Symposium, San Antonio, Texas, 2017. [oral presentation]

48. Hwang, E.S., Hyslop, T., Duong, S., Bedrosian, I., Wisner, D., Price, E., Caudle, A., Guenther, J., Hudis, C., Winer, E., Lyss, A.P.,Dickson-Witmer, D., Hieken, T., Hoefer, R., Ollila, D.W., Dickler, M., Hardman, T., Chen, Y-Y., Krings, G., Esserman, L. and Hylton, N. Phase II Single Arm Study of Preoperative letrozole for ER(+) Postmenopausal DCIS Alliance/CALGB 40903. San Antonio Breast Cancer Symposium, San Antonio, Texas, 2017. [oral presentation]

49. Cohen, J., Sabnis, A.J., Grenert, J.P., Krings, G., Cho, S.J. Horvai, A. and Davis, J.L. EWSR1-NFATC2 Gene Fusions Define A Group of Undifferentiated Tumors in Bone and Soft Tissue with Round and Epithelioid Morphology. Abstract #91. United States and Canadian Academy of Pathology (USCAP), 107th Annual Meeting, Vancouver, British Columbia, 2018. [poster]

50. Krings, G. and Chen, Y-Y. Genomic Profiling of Metaplastic Carcinoma and Associated in Situ Carcinoma of the Breast. Abstract #943. United States and Canadian Academy of Pathology (USCAP), 107th Annual Meeting, Vancouver, British Columbia, 2018. [platform]

51. Krings, G., Bean, G., Stohr, B., Hosfield, E., Shin, S.J., and Chen, Y-Y. Molecular Characterization of Mammary Pleomorphic Adenomas. Abstract #1366. United States and Canadian Academy of Pathology (USCAP), 107th Annual Meeting, Vancouver, British Columbia, 2018. [poster]

52. Shamir, E., Chu, T., Chen, Y-Y., and Krings, G. Genomic Profiling of Lobular Carcinoma in Situ (LCIS) Variants with Comparison to Classic LCIS and Invasive Lobular Carcinoma. Abstract #1386. United States and Canadian Academy of Pathology (USCAP), 107th Annual Meeting, Vancouver, British Columbia, 2018. [platform]

53. Bean, G., Shin, S.J., Hosfield, E., Jones, K., Chen, Y-Y., and Krings, G. Molecular Characterization of Small Cell/Neuroendocrine Carcinomas of the Breast. Abstract #1610. United States and Canadian Academy of Pathology (USCAP), 107th Annual Meeting, Vancouver, British Columbia, 2018. [poster]

54. Ballard, M., MacKerricher, W., Jalikis, F., Krings, G., Schmidt, R., Chen, Y-Y., Rendi, M., Dintzis, S., Troxell, M., West, R., Sibley, R., and Allison, K. Potential Impact of Proposed HER2 FISH Guideline Updates on FISH results; A Multi-Institutional Study. Abstract #2509. United States and Canadian Academy of Pathology (USCAP), 107th Annual Meeting, Vancouver, British Columbia, 2018. [poster]

55. Ballard, M., Toukatly, M., Bean, G., Jalikis, F., Krings, G., Schmidt, R., Chen, Y-Y., Dintzis, S., Troxell, M., West, R., Sibley, R., and Allison, K. Pathologic features and clinical outcomes of HER2 FISH cases with HER2:CEP17 ratio > 2.0 but < 4 HER2 signals/cell; A Multi-Institutional study. Abstract #2656. United States and Canadian Academy of Pathology (USCAP), 107th Annual Meeting, Vancouver, British Columbia, 2018. [platform]

56. Ballard, M., Toukatly, M., Bean, G., Jalikis, F., Krings, G., Schmidt, R., Chen, Y-Y., Rendi, M., Dintzis, S., Troxell, M., West, R., Sibley, R., and Allison, K.Pathologic Features and Clinical Outcomes of Breast Cancers with HER2/CEP17 ratio <2.0 and mean HER2 signals /cell >6.0 by FISH; A Multi-Institutional Study. Abstract #2663. United States and


26 of 27

Canadian Academy of Pathology (USCAP), 107th Annual Meeting, Vancouver, British Columbia, 2018. [poster]

57. Vohra, P., Krings, G., Chu, T., and Chen, Y-Y. Clinical and Pathologic Features of Invasive Breast Cancers with OncotypeDx Recurrence Score Less Than 11. Abstract #2849. United States and Canadian Academy of Pathology (USCAP), 107th Annual Meeting, Vancouver, British Columbia, 2018. [poster]

58. Mamounas, M., Wong, J., Farhner-Scott, K., Chen, Y-Y., Krings, G., Ewing, C., Esserman, L., Alvarado, M., Rugo, H., and Mukhtar, R. The impact of mitotic score versus pleomorphic subtype on disease free survival in invasive lobular carcinoma of the breast. The American Society of Breast Surgeons 19th Annual Meeting, May 2-6, 2018, Orlando, FL. [poster]

59. Mamounas, M., Wong, J., Farhner-Scott, K., Chen, Y-Y., Krings, G., Ewing, C., Esserman, L., Alvarado, M., Rugo, H., and Mukhtar, R. The impact of mitotic score versus pleomorphic subtype on disease free survival in invasive lobular carcinoma of the breast. European Breast Cancer Conference (EBCC), March 23rd, 2018, Barcelona, Spain [Poster]

60. Symmans, W.F., Yau, C., Chen, Y-Y., Datnow, B., Wei, S., Feldman, W.D., Ritter, J., Duan, X., Chen, B., Tickman, R., Sattar, H., Magliocco, A.M., Kallakury, B., Troxell, M., Asare, S., Liu, M.C., DeMichele, A., Yee, D., Berry, D.A., Esserman, L. on behalf of I-SPY 2 TRIAL Investigators and Pathologists. Residual cancer burden (RCB) is prognostic in the I-SPY 2 TRIAL Abstract #520, American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL, 2018 [Poster]

61. Camarda, R., Williams, J., Malkov, S., Zimmerman, L.J., Manning, S., Aran, D., Beardsley, A., Van de Mark, D., van Haren, J., Chen, Y., Berdan, C., Louie, S., Mahieu, C., Winkler, J., Willey, E., Gagnon, J.D., Shinoda, K., Ansel, K.M., Werb, Z., Nomura, D.C., Kajimura, S., Wittmann, T., Butte, A.J., Sanders, M.E., Liebler, D.C., Krings, G., Shepherd, J.A., and Goga, A. Tumor cell-adipocyte gap junctions activate lipolysis in breast cancer. Abstract 2398. July 2018 Cancer Research 78(13 Supplement):2398-2398 DOI: 10.1158/1538-7445.AM2018-2398

62. Shah, K.N., Bhatt, R., Rotow, J., Rohrberg, J., Olivas, V., Hemmati, G., Krings, G., Haringsma, H.J., Simmons, A.D., Harding, T.C., Goga, A., Blakely, C., Bivona, T., and Bandyopadhyay, S. Aurora kinase A drives the evolution of resistance to third-generation EGFR inhibitors in lung cancer. Abstract 1957.July 2018 Cancer Research 78(13 Supplement):1957-1957 DOI: 10.1158/1538-7445.AM2018-1957

63. Fowler, E. Harrison, B.T., Chen, Y.-Y., Krings, G., Vincent-Salomon, A., Fuhrmann, L., Chen, B., Hosfield, E.M., Barnick, S.E, Hornick, J.L., and Schnitt, S.J. Immunohistochemical Evaluation of Pan-TRK in Secretory Breast Carcinoma. #1585. United States and Canadian Academy of Pathology (USCAP), 108th Annual Meeting, National Harbor, Maryland, 2019. [platform talk, accepted]

64. Krings, G., Shamir, E.R., and Chen, Y.-Y. Genetics of Flat Epithelial Atypia and Early Neoplastic Progression in the Breast. #1018. United States and Canadian Academy of Pathology (USCAP), 108th Annual Meeting, National Harbor, Maryland, 2019. [platform talk, accepted]

65. Shamir, E.R., Vohra, P., Bean, G., Zaloudek, C., McCalmont, T.H.., Joseph, N.M., Wolsky, R.J., Garcia, J.J., Chen, Y.-Y., and Krings, G. Genomic Profiling of Basaloid Breast


27 of 27

Carcinomas Reveals Recurrent Alterations in CREBBP and Distinct Genetics from Other Triple Negative Breast Cancers. #813. United States and Canadian Academy of Pathology (USCAP), 108th Annual Meeting, National Harbor, Maryland, 2019. [platform talk, accepted]

66. Van Ziffle, J. Devine, W.P., Onodera, C., Korn, W.M., Yeh, I., Grenert, J.P., Joseph, N., Solomon, D.A., Laurance, M., Talevich, E., Bean, G., Krings, G., Stohr, B.A., Umetsu, S., Blanco, A., Bastian, B.C. Sequencing of paired tumor and normal DNA samples with the UCSF500 targeted next-generation cancer gene panel reveals frequent actionable germline alterations. American College of Medical Genetics (ACMG) Annual Meeting, Seattle, Washington, 2019. [poster, accepted]

OTHER CREATIVE ACTIVITIES

1. Lazarchick, J. and Krings, G. (2007) Anaplastic large cell lymphoma involving the bone marrow. American Society of Hematology Image Bank Jul 2007: 6-00055. Lazarchick, J. and Krings, G. (2007) Anaplastic large cell lymphoma - nodal involvement. American Society of Hematology Image Bank Jul 2007: 6-00059. Krings, G. (2015) Fibroepithelial Lesions of the Breast: Review and Update (syllabus). UCSF Current Issues in Anatomic Pathology, CME activity. Krings, G. (2016) Solid Pattern Proliferations of the Breast (syllabus). UCSF Current Issues in Anatomic Pathology, CME activity. Krings, G. (2018) Updates on Diagnosis and Management of Borderline Breast Lesions on Core Needle Biopsy (syllabus). UCSF Current Issues in Anatomic Pathology, CME activity.

curriculum vitae - pathology · curriculum vitae name: gregor krings, md, phd position: assistant...

Documents